Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is now ...
Deno 1.21 has been released. This latest upgrade to the JavaScript/TypeScript runtime features improvements to the REPL (read-evaluate-print loop) and a move away from default type-checking. The Deno ...
Zacks.com on MSN
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback